Page last updated: 2024-11-13

urotensin ii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID46225600
CHEMBL ID593662
MeSH IDM0094510

Synonyms (11)

Synonym
CHEMBL593662
urotensin-ii
urotensin 2
urotensin ii (human)
AKOS024456722
urotensin ii human, >=97% (hplc), synthetic
Q6590402
CS-0028696
HY-P1164
bdbm50517314
DTXSID801336323
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urotensin-2 receptorRattus norvegicus (Norway rat)Ki0.00080.00080.04090.1210AID1182034
Urotensin-2 receptorHomo sapiens (human)Ki0.00430.00080.67724.0000AID1182034; AID1571995
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Urotensin-2 receptorRattus norvegicus (Norway rat)EC50 (µMol)0.00300.00300.00320.0033AID1571996
Urotensin-2 receptorHomo sapiens (human)EC50 (µMol)0.00350.00300.46691.1220AID1571999; AID375521
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
signal transductionUrotensin-2 receptorHomo sapiens (human)
blood circulationUrotensin-2 receptorHomo sapiens (human)
regulation of blood pressureUrotensin-2 receptorHomo sapiens (human)
blood vessel diameter maintenanceUrotensin-2 receptorHomo sapiens (human)
neuropeptide signaling pathwayUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein-coupled receptor activityUrotensin-2 receptorHomo sapiens (human)
urotensin II receptor activityUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneUrotensin-2 receptorHomo sapiens (human)
membraneUrotensin-2 receptorHomo sapiens (human)
plasma membraneUrotensin-2 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID375528Antagonist activity at human recombinant urotensin 2 receptor expressed in CHO cells assessed as inhibition of urotensin 2-induced intracellular calcium mobilization at up to 10 uM2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
AID1182037Competitive antagonist activity at UT receptor in rat aorta assessed as effect on urotensin-2-induced contraction2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
AID1714268Agonist activity at U-IIR in pig aorta VSMC assessed as increase of ERK1/2 phosphorylation at 500 nM incubated for 15 mins by Western blot analysis relative to control2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.
AID1714269Agonist activity at U-IIR in pig aorta VSMC assessed as increase of ERK1/2 phosphorylation at 5 nM incubated for 15 mins by Western blot analysis relative to control2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.
AID1572000Agonist activity at urotensin 2 receptor (unknown origin) expressed in HEK293 cells co-expressing Gq-polycistronic BRET biosensor assessed as induction of Gq activation measured for 5 mins by luminescence detection based BRET assay relative to URP2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.
AID1182036Agonist activity at UT receptor in rat aorta assessed as contraction relative to urotensin-22014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
AID1182035Agonist activity at UT receptor in rat aorta assessed as contraction2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
AID1182034Displacement of [125I]urotensin-2 from human recombinant UT receptor expressed in CHO-K1 cells by scintillation counting method2014Journal of medicinal chemistry, Jul-24, Volume: 57, Issue:14
Lead optimization of P5U and urantide: discovery of novel potent ligands at the urotensin-II receptor.
AID1714272Agonist activity at U-IIR in pig aorta VSMC assessed as increase of ERK1/2 phosphorylation incubated for 15 mins by Western blot analysis relative to control2016Journal of medicinal chemistry, 11-23, Volume: 59, Issue:22
Urolinin: The First Linear Peptidic Urotensin-II Receptor Agonist.
AID1310776Partial agonist activity at UT2 receptor in Sprague-Dawley rat thoracic aorta ring assessed as induction of aortic contractions at 10 to 100 uM relative to KCl2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
Urotensin II((4-11)) Azasulfuryl Peptides: Synthesis and Biological Activity.
AID1571995Displacement of [125I]-URP or human [125I[-urotensin-2 from human urotensin 2 receptor expressed in HEK293 or CHOK1 cells after 2 hrs by gamma-counting assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.
AID375521Antagonist activity at human recombinant urotensin 2 receptor expressed in CHO cells assessed as inhibition of urotensin 2-induced intracellular calcium mobilization2009Journal of medicinal chemistry, Jul-09, Volume: 52, Issue:13
Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.
AID1571996Agonist activity at urotensin 2 receptor in Sprague-Dawley rat thoracic aortic ring assessed as induction of contraction relative to KCl-induced contraction2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.
AID1571999Agonist activity at urotensin 2 receptor (unknown origin) expressed in HEK293 cells co-expressing Gq-polycistronic BRET biosensor assessed as induction of Gq activation measured for 5 mins by luminescence detection based BRET assay2019Journal of medicinal chemistry, 02-14, Volume: 62, Issue:3
Functional Selectivity Revealed by N-Methylation Scanning of Human Urotensin II and Related Peptides.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 40.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index40.99 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index5.08 (4.65)
Search Engine Demand Index51.19 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (40.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]